Open label phase: mg) Phase III Randomised, HIV-infected ART 867 96 weeks of double naive adults randomised, multicentre, blinded Commenced active mg) + treatment, controlled optional study Stribild rollover extension to OR Stribild + 48 week data presented only Randomised, HIV-infected ART 866 96 of double blind, adults randomised, multicentre, blinded Commenced active mg) + treatment, 2013 controlled optional study Stribild rollover extension to OR Stribild + 48 week data presented only Randomised, Virologically 1,436 Treatment 96 weeks for open label suppressed HIV Group 1: comparative multi centre, infected adults Switch to phase, option Commenced active to continue 2013 controlled = treatment 1,000) until it becomes Treatment commercially Group 2: Stay available or on pre-existing until FTC/TDF+3rd development Agent regimen is (Stribild, ATR, terminated. ATV/co+TVD, 48 week data or ATV/r+TVD presented (n = 500) only
Open label phase: mg) Phase III Commenced Randomised, double multicentre, active controlled study HIV-infected ART naive adults 867 mg) + Stribild OR Stribild + 96 weeks of randomised, blinded treatment, optional rollover extension to 48 week data presented only Commenced 2013 Randomised, double blind, multicentre, active controlled study HIV-infected ART adults 866 mg) + Stribild OR Stribild + 96 of randomised, blinded treatment, optional rollover extension to 48 week data presented only Commenced 2013 Randomised, open label multi centre, active controlled Virologically suppressed HIV infected adults 1,436 Treatment Group 1: Switch to = 1,000) Treatment Group 2: Stay on pre-existing FTC/TDF+3rd Agent regimen (Stribild, ATR, ATV/co+TVD, or ATV/r+TVD (n = 500) 96 weeks for comparative phase, option to continue treatment until it becomes commercially available or until development is terminated. 48 week data presented only
auspar-elvitegravir-160628.docx